Skip NavigationSkip to Content

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes

  1. Author:
    O'Brien,Sean
    Swanstrom,Adrienne
    Pegu, Amarendra
    Ko, Sung-Youl
    Immonen,Taina
    Del Prete,Greg
    Fennessey,Christine
    Gorman, Jason
    Foulds, Kathryn E.
    Schmidt, Stephen D.
    Doria-Rose, Nicole
    Williamson, Carolyn
    Hatziioannou, Theodora
    Bieniasz, Paul D.
    Li, Hui
    Shaw, George M.
    Mascola, John R.
    Koup, Richard A.
    Kwong, Peter D.
    Lifson,Jeffrey
    Roederer, Mario
    Keele,Brandon
  2. Author Address

    Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Frederick, MD 21701 USA.NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.Univ Cape Town, Div Med Virol, Cape Town, South Africa.Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa.Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
    1. Year: 2019
    2. Date: APR
    3. Epub Date: 2019 04 03
  1. Journal: PLoS pathogens
  2. PUBLIC LIBRARY SCIENCE,
    1. 15
    2. 4
    3. Pages: e1007632
  3. Type of Article: Article
  4. Article Number: e1007632
  5. ISSN: 1553-7366
  1. Abstract:

    Chimeric Simian-Human Immunodeficiency Viruses (SHIVs) are an important tool for evaluating anti-HIV Env interventions in nonhuman primate (NHP) models. However, most unadapted SHIVs do not replicate well in vivo limiting their utility. Furthermore, adaptation in vivo often negatively impacts fundamental properties of the Env, including neutralization profiles. Transmitted/founder (T/F) viruses are particularly important to study since they represent viruses that initiated primary HIV-1 infections and may have unique attributes. Here we combined in vivo competition and rational design to develop novel subtype C SHIVs containing T/F envelopes. We successfully generated 19 new, infectious subtype C SHIVs, which were tested in multiple combinatorial pools in Indian-origin rhesus macaques. Infected animals attained peak viremia within 5 weeks ranging from 10(3) to 10(7) vRNA copies/mL. Sequence analysis during primary infection revealed 7 different SHIVs replicating in 8 productively infected animals with certain clones prominent in each animal. We then generated 5 variants each of 6 SHIV clones (3 that predominated and 3 undetectable after pooled in vivo inoculations), converting a serine at Env375 to methionine, tyrosine, histidine, tryptophan or phenylalanine. Overall, most Env375 mutants replicated better in vitro and in vivo than wild type with both higher and earlier peak viremia. In 4 of these SHIV clones (with and without Env375 mutations) we also created mutations at position 281 to include serine, alanine, valine, or threonine. Some Env281 mutations imparted in vitro replication dynamics similar to mutations at 375; however, clones with both mutations did not exhibit incremental benefit. Therefore, we identified unique subtype C T/F SHIVs that replicate in rhesus macaques with improved acute phase replication kinetics without altering phenotype. In vivo competition and rational design can produce functional SHIVs with globally relevant HIV-1 Envs to add to the growing number of SHIV clones for HIV-1 research in NHPs. Author summary Nonhuman primates provide useful models for studying HIV transmission, pathogenesis and cure strategies. Due to species-specific antiviral factors, however, HIV cannot replicate in Asian macaques directly. Some chimeric viruses incorporating HIV Envelope genes in simian immunodeficiency virus (SIV) backbone can replicate to sufficient levels in Asian macaques to permit evaluation of anti-HIV interventions. Here we describe the generation of new SHIV clones unique to the field in 4 important ways. First, these clones were generated from the globally relevant HIV-1 subtype C, which is the most prevalent form of HIV globally and is found predominately in sub-Saharan Africa where the pandemic is particularly devastating but is poorly represented among SHIVs studied to date. Second, we utilized Envelope genes from viruses that established primary infection, making these clones particularly useful in transmission studies. Third, these clones were not generated by animal passage, which may alter some of the unique properties of these Envelopes. Finally, we used direct within animal competition studies and two targeted mutations to select highly replicative clones. We provide here both the discovery of new SHIV clones, and also a process to generate additional clones in the future.

    See More

External Sources

  1. DOI: 10.1371/journal.ppat.1007632
  2. PMID: 30943274
  3. WOS: 000466742700008

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel